THX Pharma Société Anonyme (EPA:ALTHX)

Market Cap	45.39M +492.1%
Revenue (ttm)	806.05K -64.7%
Net Income	-3.00M
EPS	-0.22
Shares Out	13.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,154
Open	3.320
Previous Close	3.290
Day's Range	3.220 - 3.350
52-Week Range	0.770 - 5.100
Beta	1.52
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 29, 2026

About EPA:ALTHX

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 12
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALTHX

Financial Performance

In 2025, EPA:ALTHX's revenue was 806,045, a decrease of -64.70% compared to the previous year's 2.28 million. Losses were -3.00 million, 70.0% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 23, 2026

Data Sources Report a data error